A topic concerning a grant from CIRM (California Institute for Regenerative Medicine) for the Phase IIb clinical trial of SB623 in chronic-phase cerebral infarction, with receipt of the grant tied to patient enrollment, follow-up and the final report. It covers the acquisition of a grant linked to a specific clinical trial and the conditions for receiving it.